Want to see APRE full AI Analyst Report?
APRE Stock Chart & Stats
$1.00
-$0.03(-0.72%)
At close: 4:00 PM EST
$1.00
-$0.03(-0.72%)
Day’s Range― - ―
52-Week Range$0.55 - $2.22
Previous CloseN/A
Volume2.88K
Average Volume (3M)55.77K
Market Cap
$9.01M
Enterprise Value-$41.40M
Total Cash (Recent Filing)$46.47M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.10
Next Earnings
Aug 06, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.75
Shares Outstanding12,382,776
10 Day Avg. Volume84,633
30 Day Avg. Volume55,770
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.45
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-4.59
Enterprise Value/Revenue-350.53
Enterprise Value/Gross Profit23.01
Enterprise Value/Ebitda3.47
Forecast
1Y Price Target
$4.30Price Target Upside330.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.69
Revenue Forecast (FY)$1.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtAprea's virtually debt-free balance sheet materially reduces refinancing and interest-rate risk, giving management flexibility to fund clinical programs and prioritize R&D without near-term interest obligations. This structural strength improves survival odds during extended development timelines.
$30M Financing Extends RunwayThe oversubscribed $30M private placement meaningfully extends cash runway into Q1 2028, funding expanded APR-1051 enrollment and R&D. Reliable near-term funding reduces the immediate probability of dilutive emergency raises and allows multi-quarter execution of planned trials and readouts.
Clinical Signal For APR-1051Observed partial responses and tolerability in the Phase 1 APR-1051 study provide early efficacy and safety signal. Durable clinical activity in biomarker-defined populations can de-risk the lead program, improve partnerability, and support larger trials and future commercialization strategies.
Bears Say
Persistent Cash BurnOperating and free cash flow remain consistently negative (TTM ~ -$12.2M), indicating ongoing burn despite improvement versus earlier periods. Continued cash outflow requires future funding rounds or partnerships, creating dilution and execution risk over the medium term if trial costs rise or enrollment slows.
Ongoing Losses & Volatile RevenueAprea operates at material net losses with inconsistent revenue, including a TTM revenue decline of ~58%. Lack of commercial revenues forces reliance on capital markets to finance R&D, compresses margins long-term, and leaves returns on equity persistently negative absent successful late-stage outcomes.
ATRN-119 Monotherapy PausedPausing ATRN-119 monotherapy to pursue combinations signals uncertainty about standalone efficacy and delays clear development paths. This increases program execution risk, shifts resources and timelines, and concentrates the company's near-term scientific and commercial hopes on fewer, later-stage catalysts.
Aprea Therapeutics News
APRE FAQ
What was Aprea Therapeutics Inc’s price range in the past 12 months?
Aprea Therapeutics Inc lowest stock price was $0.55 and its highest was $2.22 in the past 12 months.
What is Aprea Therapeutics Inc’s market cap?
Aprea Therapeutics Inc’s market cap is $9.01M.
When is Aprea Therapeutics Inc’s upcoming earnings report date?
Aprea Therapeutics Inc’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were Aprea Therapeutics Inc’s earnings last quarter?
Aprea Therapeutics Inc released its earnings results on May 13, 2026. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.212 by -$0.008.
Is Aprea Therapeutics Inc overvalued?
According to Wall Street analysts Aprea Therapeutics Inc’s price is currently Undervalued.
Does Aprea Therapeutics Inc pay dividends?
Aprea Therapeutics Inc does not currently pay dividends.
What is Aprea Therapeutics Inc’s EPS estimate?
Aprea Therapeutics Inc’s EPS estimate is -0.18.
How many shares outstanding does Aprea Therapeutics Inc have?
Aprea Therapeutics Inc has 12,382,776 shares outstanding.
What happened to Aprea Therapeutics Inc’s price movement after its last earnings report?
Aprea Therapeutics Inc reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.212. Following the earnings report the stock price went down -2.222%.
Which hedge fund is a major shareholder of Aprea Therapeutics Inc?
Currently, no hedge funds are holding shares in APRE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Aprea Therapeutics Inc
Aprea Therapeutics, Inc. is a biopharmaceutical company in its clinical development stage, dedicated to discovering and marketing innovative cancer treatments. Their therapeutic approach centers on modulating DNA damage response pathways. The company's primary drug candidate, ATRN-119, is an oral ATR inhibitor currently undergoing Phase 1/2a clinical trials for patients with advanced solid tumors. Beyond this lead compound, Aprea's developmental pipeline includes ATRN-Backup, which is also an ATR inhibitor; ATRN-W1051, being explored for its anti-tumor effects; and ATRN-DDRi. Aprea Therapeutics, Inc. is headquartered in Boston, Massachusetts.
APRE Stock 12 Month Forecast
Average Price Target
$4.30
▲(330.00% Upside)
Technical Analysis
Ownership Overview
6.50% Insiders
0.86% Mutual Funds
15.36% Other Institutional Investors
77.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---